2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. CDK

CDK

Cyclin dependent kinase

CDK

Related Products

PDF 1.19 MB

CDKs (Cyclin-dependent kinases) are serine-threonine kinases first discovered for their role in regulating the cell cycle. They are also involved in regulating transcription, mRNA processing, and the differentiation of nerve cells. CDKs are relatively small proteins, with molecular weights ranging from 34 to 40 kDa, and contain little more than the kinase domain. In fact, yeast cells can proliferate normally when their CDK gene has been replaced with the homologous human gene. By definition, a CDK binds a regulatory protein called a cyclin. Without cyclin, CDK has little kinase activity; only the cyclin-CDK complex is an active kinase.

There are around 20 Cyclin-dependent kinases (CDK1-20) known till date. CDK1, 4 and 5 are involved in cell cycle, and CDK 7, 8, 9 and 11 are associated with transcription.

CDK levels remain relatively constant throughout the cell cycle and most regulation is post-translational. Most knowledge of CDK structure and function is based on CDKs of S. pombe (Cdc2), S. cerevisia (CDC28), and vertebrates (CDC2 and CDK2). The four major mechanisms of CDK regulation are cyclin binding, CAK phosphorylation, regulatory inhibitory phosphorylation, and binding of CDK inhibitory subunits (CKIs).

CDK Isoform Specific Products:

CDK Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-156705
    CDK7-IN-25
    		Inhibitor
    CDK7-IN-25 (CY-16-1) is a CDK-7 inhibitor (IC50<1nM) that can be used in cancer research.
    CDK7-IN-25
  • HY-176444
    CDK2 degrader 6
    		Degrader
    CDK2 degrader 6 (compound 6) is an orally active and potent CDK2 molecular glue degrader with a DC50 of 46.5 nM. CDK2 degrader 6 can be used in the study of breast cancer.
    CDK2 degrader 6
  • HY-139651
    CDK2-IN-7
    		Inhibitor
    CDK2-IN-7 is a CDK2 inhibitor for researching cancer (IC50 < 50 nM).
    CDK2-IN-7
  • HY-164376
    CDK4/6-IN-21
    		Inhibitor
    CDK4/6-IN-21 (compound I-52) is a CDK4/6 inhibitor with IC50 values of 3.88 and 3.31 nM for CDK4 and CDK6, respectively. CDK4/6-IN-21 has antitumor activity.
    CDK4/6-IN-21
  • HY-155177
    CDK9-IN-27
    		Inhibitor
    CDK9-IN-27 (Compound 6a) is a CDK9 inhibitor (IC50s: 0.424 μM). CDK9-IN-27 induces apoptosis and cell cycle arrest at S stage. CDK9-IN-27 has cytotoxic action against HepG2, HCT-116 and MCF-7 cell lines, with IC50s of 10.31-40.34 μM. CDK9-IN-27 can be used for cancer research.
    CDK9-IN-27
  • HY-155966
    CDK2-IN-19
    		Inhibitor
    CDK2-IN-19 (Compound 32) is a selective and orally active CDK2 inhibitor (Ki: 0.18 nM). CDK2-IN-19 shows anticancer activity in mice bearing OVCAR3 tumors.
    CDK2-IN-19
  • HY-150572
    CDK2-IN-11
    		Inhibitor
    CDK2-IN-11 (compound 9d) is a potent CDK2 inhibitor with an IC50 of 6.4 μM, and KI values of 23.4 nM, 56.3 nM and 44.3 nM for hCA II, hCA IX and hCA XII, respectively. CDK2-IN-11 can be used for researching anticancer.
    CDK2-IN-11
  • HY-150609
    SHP2/CDK4-IN-1
    		Inhibitor
    SHP2/CDK4-IN-1 (compound 10) is an orally active and potent SHP2 and CDK4 dual inhibitor, with IC50 values of 4.3 and 18.2 nM, respectively. SHP2/CDK4-IN-1 effectively induces G0/G1 arrest to prevent the proliferation of TNBC cell lines. SHP2/CDK4-IN-1 shows significant antitumor efficacy in the EMT6 syngeneic mouse model. SHP2/CDK4-IN-1 can be used for triple-negative breast cancer (TNBC) research.
    SHP2/CDK4-IN-1
  • HY-139449
    CDK4/6-IN-5
    		Inhibitor
    CDK4/6-IN-5 is a potent CDK4 and CDK6 inhibitor with Kis of 0.2 and 4.4 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively. (from patent WO2019207463A1 example A93).
    CDK4/6-IN-5
  • HY-RS02381
    CDK4 Human Pre-designed siRNA Set A
    		Inhibitor

    CDK4 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    CDK4 Human Pre-designed siRNA Set A
    CDK4 Human Pre-designed siRNA Set A
  • HY-147527
    CDK8-IN-5
    		Inhibitor
    CDK8-IN-5 is a potent CDK8 inhibitor with an IC50 of 72 nM. CDK8-IN-5 shows anti-inflammatory activities with 43% IL-10 enhancement rate. CDK8-IN-5 has the potential for the research of inflammatory bowel disease.
    CDK8-IN-5
  • HY-115943
    Anticancer agent 30
    		Inhibitor
    Anticancer agent 30 (compound 6f-Z), a 3-arylidene-2-oxindole derivative, is a selective CDK2 inhibitor with potent anticancer activity.
    Anticancer agent 30
  • HY-123369
    BMI-1026
    		Inhibitor
    BMI-1026 is a cyclin-dependent kinase 1 (Cdk1) inhibitor with IC50 of 2.3 nM. BMI-1026 induces apoptosis by arresting the G2-M phase.
    BMI-1026
  • HY-168067
    CDK-IN-14
    		Inhibitor
    CDK-IN-14 (B34) is a CDK2 inhibitor (IC50=0.097 μM) with anti-hepatocellular carcinoma activity. CDK-IN-14 blocks the cell cycle of HepG-2 cancer cells through a caspase-mediated mechanism and induces apoptosis.
    CDK-IN-14
  • HY-125001
    JH-VIII-49
    		Inhibitor
    JH-VIII-49 (compound 10) is a potent and selective CDK8 inhibitor (IC50=16 nM) with excellent biological activity. JH-VIII-49 promotes CDK8 inhibition through its steroid backbone design. JH-VIII-49 can be used in the synthesis of PROTAC as a target protein ligand of JH-XI-10-02 (HY-111518).
    JH-VIII-49
  • HY-RS02383
    CDK4 Rat Pre-designed siRNA Set A
    		Inhibitor

    CDK4 Rat Pre-designed siRNA Set A contains three designed siRNAs for CDK4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    CDK4 Rat Pre-designed siRNA Set A
    CDK4 Rat Pre-designed siRNA Set A
  • HY-143432
    Cdc7-IN-18
    		Inhibitor
    Cdc7-IN-18 (compound 1-2) is a potent CDC7 inhibitor with an IC50 of 1.29 nM for Cdc7/DBF4 enzyme. Cdc7-IN-18 shows antiproliferative activities with IC50 of 53.62 nM in COLO205 cells.
    Cdc7-IN-18
  • HY-RS02396
    Cdk7 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Cdk7 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdk7 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Cdk7 Mouse Pre-designed siRNA Set A
    Cdk7 Mouse Pre-designed siRNA Set A
  • HY-N0417R
    Cucurbitacin E (Standard)
    		Inhibitor
    Cucurbitacin E (Standard) is the analytical standard of Cucurbitacin E. This product is intended for research and analytical applications. Cucurbitacin E is a natural compound which from Cucurbitaceae plants. Cucurbitacin E significantly suppresses the activity of the cyclin B1/CDC2 complex.
    Cucurbitacin E (Standard)
  • HY-P1906A
    [pThr3]-CDK5 Substrate TFA
    [pThr3]-CDK5 Substrate TFA is an effective Phospho-Thr3CDK5 Substrate. [pThr3]-CDK5 Substrate is derived from the sequence of the histone H1 peptide that docks in the active site of CDK5. [pThr3]-CDK5 Substrate is phosphorylated by CDK5 with a Km value of 6 µM.
    [pThr3]-CDK5 Substrate TFA
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
CDK Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.